Chronic viral hepatitis: Liver biopsy, yes or no?

Revista Espanola de Enfermedades Digestivas

Volumn 94, Issue 10, 2002, Pages 619-624

  Castellano Tortajada, G ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; DNA ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

AMBULATORY CARE; ASCITES; BLOOD CLOTTING DISORDER; DEATH; DELTA AGENT HEPATITIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ECHOGRAPHY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS NON A NON B; HEPATITIS VIRUS NON A NON B; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LAPAROSCOPY; LIVER BIOPSY; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER CYST; LIVER FIBROSIS; LIVER HEMANGIOMA; LIVER INJURY; MORBIDITY; MORTALITY; NEEDLE; OBSTRUCTIVE JAUNDICE; POPULATION RESEARCH; PUBLIC HEALTH; REVIEW; VIRUS TRANSMISSION; BIOPSY; CHRONIC DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER; PATHOLOGY; PROGNOSIS; VIRUS HEPATITIS;

BIOPSY; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; LIVER; PROGNOSIS;

EID: 0141789912     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Martínez-Montiel MP, Castellano G, Colina F, Pérez-Sola A, Solís JA. Hepatitis crónica activa. Análisis de 207 casos. An Med Intern 1988; 5: 183-9.
2. Dusheiko G. Hepatitis B. En: Rodés J, Benhamou JP, Bircher J, McIntyre N, Rizzetto M, eds. Tratado de Hepatología Clínica. Barcelona: Masson S.A., 2001. p. 980-1006.
3. Alberti A, Bortolotti F. Hepatitis C. En: Rodés J, Benhamou JP, Bircher J, McIntyre N, Rizzetto M eds. Tratado de Hepatología Clínica. Barcelona: Masson S.A., 2001. p. 1014-41.
4. Sánchez-Tapias JM. Natural history of chronic hepatitis B. En: Buti M, Esteban R, Guardia J eds. Viral Hepatitis. Madrid: Acción Médica SA, 2000. p. 21-31.
5. Castellano G. The natural history of hepatitis C virus infection. Nephrol Dial Transplant 2000; 15: 19-23.
6. Lok ASF, Gutaratnam NT. Diagnosis of hepatitis C. J Hepatol 1997; 26 (Supl. 1): 48S-56S.
7. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy results of a nation-wide survey in Switzerland. Dig Dis Sci 1993; 38: 1480-4.
8. Van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: questions and answers. Semin Liver Dis 1995; 15: 340-59.
9. García G, Keefe EB. Liver biopsy in chronic hepatitis C: routine or selective. Am J Gastroenterol 2001; 96: 3053-5.
10. Spinzi G, Minoli G. To biopsy or not to biopsy. Hepatology 2001; 34: 438-9.
11. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology 2000; 32: 477-81.
12. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C. Risks, benefits, and costs. JAMA 1998; 280: 2088-93.
13. Wong JB, Koff RS, for the International Hepatitis Interventional Therapy Group. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. Ann Intern Med 2000; 133: 665-75.
14. Kisloff B. Periodic liver biopsy for mild hepatitis C. Ann Intern Med 2000; 135: 381-2.
15. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32: 904-9.
16. National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997; 26 (Supl. 1): 2S-10S.
17. Consensus Statement. EASL international consensus conference on hepatitis C. J Hepatol 1999; 30: 956-61.
18. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26 (Supl. 1): 57S-61S.
19. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200.
20. De Groote J, Desmet VJ, Gedigk P, Popper H, Scheuer PJ, Thaler N, et al. A classification of chronic hepatitis. Lancet 1968; 2: 626-8.
21. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
22. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
23. Bedossa P, and the French METAVIR Cooperative Group. Inter-and intra-observer variation in the assessment of liver biopsy of chronic hepatitis. Hepatology 1994; 20: 15-20.
24. Bedossa P, Poynard T, for the French METAVIR Group. An algorithm for the grading of activity in chronic hepatitis. Hepatology 1996; 24: 289-93.
25. Koukoulis GK. Chronic hepatitis C: grading, staging, and searching for reliable predictors of outcome. Hum Pathol 2001; 32: 899-903.
26. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.
27. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
28. Lok AS. Treatment of chronic hepatitis C. J Viral Hepat 1994; 1: 105-24.
29. Saracco G, Rizzetto M. Tratamiento de la hepatitis vírica crónica. En: Rodés J, Benhamou JP, Bircher J, McIntyre N, Rizzetto M, eds. Tratado de Hepatología Clínica. Barcelona: Masson S.A., 2001. p. 1056-73.
30. Fernández I, Castellano G, Domingo MJ, Fuertes A, Colina F, Canga F, et al. Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection. Scand J Gastroenterol 1997; 32: 70-6.
31. Poynard T, McHutchinson J, Goodman Z, Ling MH, Albrecht J, for the ALGOVIRC Projet Group. Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31: 211-8.
32. Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee SS, Balan L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
33. Andriulli A, Festa V, Leandro G, Rizzetto M, and AIGO members. Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection. Dig Dis Sci 2001; 46: 1409-15.
34. Sheth SG, Flamm SL, Gordon FD. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8.
35. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998; 43: 2156-9.
36. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-6.
37. Bonacini M, Hadi G, Govindarajan S. Utility of a discriminant score for diagnosing advanced fibrosis or cirrosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1302-4.
38. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, and the MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
39. Jeffers LJ, Coelho-Little E, Cheinquer H, Vargas C, Civantos F, Alvarez L, et al. Procollagen-III peptide and chronic viral hepatitis. Am J Gastroenterol 1995; 90: 1437-40.
40. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558-63.
41. Wong VS, Hughes V, Trull A, Wight DGD, Petrik J, Alexander GJM. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998; 5: 187-92,
42. Castellano G. Criterios diagnósticos de hepatopatía crónica en la ecografía convencional. Rev Esp Ecogr Digest 2001; 3: 225-6.
43. Colin J. Cazals-Hatem D, Loriot M, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of HIV infection on chronic hepatitis B in homosexual men. Hepatology 1999: 29: 1306-10.
44. Soriano V, Bravo R, Mas A, García-Samaniego J, érrez M, González-Lahoz J. Impact of immunosuppression caused by HIV infection on the replication of hepatitis C virus. Vox Sang 1995; 69: 259-60.
45. Soto B. Sánchez-Quijano A, Rodrigo L, Del Olmo JA, ía-Bengoechea M, Hernández-Quero J, et al. HIV infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
46. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Gacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-28.